Back of the Napkin Bios
Home
Notes
Chat
My Watchlist
Archive
About
Subscribe
Sign in
Latest
Top
Discussions
Personalis Part II: Per-Test Economics, Volume Scenarios, and a Risk-Adjusted Price Target
Since We're Here, We Might As Well
20 hrs ago
•
Back of the Napkin Bios
6
3
1
Caribou Biosciences: The Off-The-Shelf Revolution
The Original is now a Bubble Proxy
May 12
•
Back of the Napkin Bios
3
1
Prime Medicine: The Word Processor
Discovery Not Recovery
May 10
•
Back of the Napkin Bios
3
1
TAM Got Larger
Reason to Recalibrate
May 5
•
Back of the Napkin Bios
1
Held Through, Added Through
What the Framework Asks For
May 4
•
Back of the Napkin Bios
2
1
A Second Leg for CorMedix
Rezzayo Hits Across All Three Pathogens, Setting Up a 2H26 Filing and 2027 Launch
May 1
•
Back of the Napkin Bios
2
3
April 2026
Queuing Up the Next One
The Next Pitch: What I'm Watching Now
Apr 29
•
Back of the Napkin Bios
4
2
1
The Biology Will Win
What I Saw in Baltimore at HIPE
Apr 27
•
Back of the Napkin Bios
41
5
6
AbCellera: The Bubble Proxy
With a Real Catalyst Inside
Apr 22
•
Back of the Napkin Bios
5
Legend Biotech: The Kelonia Read-Through
What Lilly’s Kelonia Deal Implies About a Stock the Market Has Written Off
Apr 20
•
Back of the Napkin Bios
3
2
2
The Platform Compounders: Biotech’s Best Buy-and-Hold Names
Watch for Inflecting R&D Productivity
Apr 16
•
Back of the Napkin Bios
8
1
An Important Nugget From NORD
Buried in the Deck
Apr 15
•
Back of the Napkin Bios
13
7
1
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
